DEALS: Astellas pays Theravance $65M for antibiotic
Astellas, Theravance sign co-development agreement
|
DEALS |
|||
|
WHO |
WITH |
WHAT |
SCOOP |
|
Astellas |
Theravance |
Co-development and marketing deal |
The deal involves Theravance's antibiotic telavancin. Astellas will pay $65M upfront and up to $156M in clinical and regulatory milestones. |
|
Kos Life Sciences |
Jerini |
Marketing and distribution deal |
The companies will develop, market and distribute Jerini's compound, Icatibant, in the US and Canada. |
|
DOR BioPharma |
Gastrotech Pharma |
Dor to buy Gastrotech for $9M in stock |
Gastrotech develops therapeutics based on peptide hormones to treat cancer and gastrointestinal diseases. |
|
Novartis |
Senju |
Co-development and marketing deal |
Novartis announced that it has signed a deal with Senju Pharmaceutical to develop and market Senju's glaucoma treatment Y39983. |
|
Introgen |
Colgate-Palmolive |
Co-development deal |
Introgen and Colgate-Palmolive will develop a mouthwash therapy for pre-cancerous conditions of the mouth and oral cancer. |
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
